Why Was Baby KJ's Therapy Aimed at the Liver?
Priscilla Chan says baby KJ's disease was chosen because the therapy had to reach his liver, where a product could be delivered.
The team at CHOP delivered a CRISPR therapy to edit a mutation that would have led to significant neurotoxicity and changed his life. Chan treats that delivery choice as the judgment that unlocks a first application. She also says a human test can still show renal toxicity when a kidney cell carries a receptor the drug was not supposed to hit. A single-cell atlas, including cell types that had not been predicted before the modeling, can show which cells carry that receptor before a human trial. A transcriptomic model is one way to see how different cells react to an intervention.
From the transcript
And then when we test it in human, like we see it happening and we see renal toxicity. And if you have a single-cell atlas that looks at all the different cell types, some of which actually were not predicted before we modeled them, you can start looking at which cells actually do have receptors for the target you thought you were exclusively targeting and be able to predict some of these downstream effects before we get into the human trials.
And I think that that's actually one of the more exciting applications of like a transcriptomic model to understand actually how the different cells will react when you intervene and do something. And, you know, but I think when you think about delivery mechanisms and patient care, you start that's where you start having to be creative about when you ask, like, what disease do you want to care first? There are certain diseases that will be easier to, like, deliver a therapeutic to or the risk reward is makes more sense.